Hikma Pharmaceuticals Plc (OTC:HKMPF) has received an average rating of “Hold” from the six analysts that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and one has assigned a buy recommendation to the company.
A number of brokerages have recently weighed in on HKMPF. Jefferies Group LLC raised shares of Hikma Pharmaceuticals Plc from an “underperform” rating to a “hold” rating in a research note on Monday, August 21st. Morgan Stanley reaffirmed an “equal weight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Wednesday, August 2nd. ValuEngine raised shares of Hikma Pharmaceuticals Plc from a “hold” rating to a “buy” rating in a research note on Thursday, July 27th. Finally, Goldman Sachs Group, Inc. (The) lowered shares of Hikma Pharmaceuticals Plc from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 22nd.
COPYRIGHT VIOLATION WARNING: “Hikma Pharmaceuticals Plc (HKMPF) Given Average Rating of “Hold” by Brokerages” was originally reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.truebluetribune.com/2017/10/13/hikma-pharmaceuticals-plc-hkmpf-given-average-rating-of-hold-by-brokerages.html.
Hikma Pharmaceuticals Plc Company Profile
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.